Adelis Equity Partners completed the acquisition of BioSite Group.

Adelis Equity Partners, a private equity investment firm that invests in business services, completed the acquisition of BioSite Group, an established growing company, representing top quality manufacturers of validated products for research and diagnostics. Financial terms were not disclosed. “NBG is a leader in each of the regions in which it operates. Life science research will continue to see strong underlying growth in a post-pandemic world – with a wealth of exciting new products continuously being launched. Connecting suppliers to the fragmented European research and diagnostics market enables high quality research output. We are impressed by NBG’s management team and skilled employees and recognise that the company’s services are of great value to its suppliers and customers. We look forward to supporting NBG build a truly pan-European distribution platform,” Rasmus Molander and Lene Stern, Adelis Investment Team.